Ligand Pharmaceuticals Acquires XOMA Royalty Corp

By Ahmed Jamerson • Tuesday, July 14 10:52 • Permanent Link

Ligand Pharmaceuticals completed its acquisition of XOMA Royalty on July 14, 2026, paying XOMA Royalty stockholders $39.00 in cash for each share of common stock.

In addition to the cash payment, stockholders and equity award holders received one non-transferable contingent value right per share. That CVR gives holders the right to receive a portion of 75% of any net proceeds from certain pending litigation at XOMA Royalty.

The transaction, first announced on April 27, 2026, resulted in all outstanding XOMA Royalty common shares being acquired. Following the closing, XOMA Royalty’s common stock stopped trading on Nasdaq.

The deal also marked the end of XOMA Royalty as a standalone public company after a business built around acquiring future economics tied to biotech assets and therapeutic candidates. The market has reacted to these announcements by moving the company's shares -9.16% to a price of $40.17. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.